Our top pick for
Beginners

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Updated
GlaxoSmithKline plc is a drug manufacturers-general business based in the US. GlaxoSmithKline shares (GSK) are listed on the NYSE and all prices are listed in US Dollars.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Advanced traders
Latest market close | USD$34.38 |
---|---|
52-week range | USD$29.7795 - USD$40.9784 |
50-day moving average | USD$36.3215 |
200-day moving average | USD$37.2769 |
Wall St. target price | USD$46.57 |
PE ratio | 34.1633 |
Dividend yield | USD$1.058 (3.1%) |
Earnings per share (TTM) | USD$0.992 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $34.38 from 2021-02-25
1 week (2021-02-24) | -0.87% |
---|---|
1 month (2021-02-03) | -2.94% |
3 months (2020-12-03) | -7.75% |
6 months (2020-09-03) | -11.87% |
1 year (2020-03-03) | -16.76% |
---|---|
2 years (2019-03-01) | -14.88% |
3 years (2018-03-02) | 36.22 |
5 years (2016-03-03) | 39.18 |
Valuing GlaxoSmithKline stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of GlaxoSmithKline's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
GlaxoSmithKline's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 34x. In other words, GlaxoSmithKline shares trade at around 34x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
GlaxoSmithKline's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 7.9184. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into GlaxoSmithKline's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Gross profit TTM | USD$23.2 billion |
---|---|
Return on assets TTM | 6.29% |
Return on equity TTM | 32.62% |
Profit margin | 16.86% |
Book value | $2.406 |
Market capitalisation | USD$84.8 billion |
TTM: trailing 12 months
There are currently 19.4 million GlaxoSmithKline shares held short by investors – that's known as GlaxoSmithKline's "short interest". This figure is 41.4% up from 13.7 million last month.
There are a few different ways that this level of interest in shorting GlaxoSmithKline shares can be evaluated.
GlaxoSmithKline's "short interest ratio" (SIR) is the quantity of GlaxoSmithKline shares currently shorted divided by the average quantity of GlaxoSmithKline shares traded daily (recently around 6.6 million). GlaxoSmithKline's SIR currently stands at 2.94. In other words for every 100,000 GlaxoSmithKline shares traded daily on the market, roughly 2940 shares are currently held short.
However GlaxoSmithKline's short interest can also be evaluated against the total number of GlaxoSmithKline shares, or, against the total number of tradable GlaxoSmithKline shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case GlaxoSmithKline's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 GlaxoSmithKline shares in existence, roughly 10 shares are currently held short) or 0% of the tradable shares (for every 100,000 tradable GlaxoSmithKline shares, roughly 0 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against GlaxoSmithKline.
Find out more about how you can short GlaxoSmithKline stock.
Dividend payout ratio: 70.68% of net profits
Recently GlaxoSmithKline has paid out, on average, around 70.68% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 6.25% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), GlaxoSmithKline shareholders could enjoy a 6.25% return on their shares, in the form of dividend payments. In GlaxoSmithKline's case, that would currently equate to about $1.058 per share.
GlaxoSmithKline's payout ratio would broadly be considered high, and as such this stock could appeal to those looking to generate an income. Bear in mind however that companies should normally also look to re-invest a decent amount of net profits to ensure future growth.
GlaxoSmithKline's most recent dividend payout was on 8 April 2021. The latest dividend was paid out to all shareholders who bought their shares by 18 February 2021 (the "ex-dividend date").
GlaxoSmithKline's shares were split on a 2:1 basis on 12 November 1991. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your GlaxoSmithKline shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for GlaxoSmithKline shares which in turn could have impacted GlaxoSmithKline's share price.
Over the last 12 months, GlaxoSmithKline's shares have ranged in value from as little as $29.7795 up to $40.9784. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while GlaxoSmithKline's is 0.3633. This would suggest that GlaxoSmithKline's shares are less volatile than average (for this exchange).
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, HIV, immuno-inflammation, oncology, anti-viral, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterial, and dermatology. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories. The company offers its consumer healthcare products in the form of nasal sprays, tablets, syrups, lozenges, gum and trans-dermal patches, caplets, infant syrup drops, liquid filled suspension, wipes, gels, effervescents, toothpastes, toothbrushes, mouthwashes, denture adhesives and cleansers, topical creams and non-medicated patches, lip balm, gummies, and soft chews. It has collaboration agreements with 23andMe; Merck KGaA; Lyell Immunopharma; Novartis; CEPI; Innovax and Xiamen University; VBI; Viome; Sanofi SA; and CureVac. The company also has an agreement with Vir Biotechnology, Inc for research and development of new therapies for influenza and other respiratory viruses. GlaxoSmithKline plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.
Everything we know about the Achilles Therapeutics plc IPO, plus information on how to buy in.
Everything we know about the SEMrush Holdings Inc IPO, plus information on how to buy in.
Everything we know about the ChargePoint IPO, plus information on how to buy in.
Everything we know about the Kaltura Inc IPO, plus information on how to buy in.
Everything we know about the Rocket Lab IPO, plus information on how to buy in.
Everything we know about the Soho House IPO, plus information on how to buy in.
Everything we know about the VIZIO IPO, plus information on how to buy in.
Everything we know about the IDW Media Holdings Inc IPO, plus information on how to buy in.
Everything we know about the Karooooo Ltd IPO, plus information on how to buy in.
Everything we know about the Connect Biopharma Holdings Limited IPO, plus information on how to buy in.